Previous Section
Review Articles
1. Drug resistance and methylation in myelodysplastic syndrome.
- Author
- Vidal DO; Lopes LF; Valera ET;
- Institution
- Laboratory of Molecular Biology and Genomics, Ludwig Institute for Cancer Research--Sao Paulo Branch, Brazil. dvidal@ludwig.org.br
- Journal
- Curr Pharm Biotechnol. 2007 Apr;8(2):77-81.
- Abstract URL
- Click here to view abstract
2. The spectrum of molecular aberrations in myelodysplastic syndromes: in the shadow of acute myeloid leukemia.
- Author
- Steensma DP;
- Institution
- Journal
- Haematologica. 2007 Jun;92(6):723-7.
3. Comparison of megadose methylprednisolone versus conventional dose prednisolone in hematologic disorders.
- Author
- Yetgin S; Ozsoylu S;
- Institution
- Department of Pediatric Hematology, Faculty of Medicine, Hacettepe University, Ihsan Dogramaci Children's Hospital, Ankara, Turkey. yetgins@hacettepe.edu.tr
- Journal
- J Pediatr Hematol Oncol. 2007 Apr;29(4):253-9.
- Abstract URL
- Click here to view abstract
4. Risk-based management of myelodysplastic syndrome.
- Author
- Steensma DP; Tefferi A;
- Institution
- Mayo Clinic, Rochester, Minnesota, USA. steensma.david@mayo.edu
- Journal
- Oncology (Williston Park). 2007 Jan;21(1):43-54; discussion 57-8, 62.
- Abstract URL
- Click here to view abstract
5. Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer.
- Author
- Stevenson JG; Natale JJ;
- Institution
- Department of Pharmacy Services, University of Michigan Hospitals and Health Centers, and the College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-0008, USA. jimsteve@med.umich.edu
- Journal
- Pharmacotherapy. 2007 Mar;27(3):434-46.
- Abstract URL
- Click here to view abstract
6. Deferasirox.
- Author
- Stumpf JL;
- Institution
- University of Michigan Health System and College of Pharmacy, Ann Arbor, Michigan, USA.
- Journal
- Am J Health Syst Pharm. 2007 Mar 15;64(6):606-16.
- Abstract URL
- Click here to view abstract
7. Recent advances in myelodysplastic syndromes.
- Author
- Shadduck RK; Latsko JM; Rossetti JM; Haq B; Abdulhaq H;
- Institution
- Western Pennsylvania Cancer Institute, Western Pennsylvania Hospital, Pittsburgh, PA 15224, USA. rshadduck@msn.com
- Journal
- Exp Hematol. 2007 Apr;35(4 Suppl 1):137-43.
- Abstract URL
- Click here to view abstract
8. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
- Author
- Jabbour E; Kantarjian HM; Koller C; Taher A;
- Institution
- Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA.
- Journal
- Cancer. 2008 Mar 1;112(5):1089-95.
- Abstract URL
- Click here to view abstract
9. Treatment strategies in myelodysplastic syndromes.
- Author
- Atallah E; Garcia-Manero G;
- Institution
- Department of Neoplastic Diseases, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Journal
- Cancer Invest. 2008 Mar;26(2):208-16.
- Abstract URL
- Click here to view abstract
10. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes.
- Author
- Giagounidis A; Fenaux P; Mufti GJ; Muus P; Platzbecker U; Sanz G; Cripe L; Von Lilienfeld-Toal M; Wells RA;
- Institution
- St. Johannes Hospital, Medizinische Klinik II, An der Abtei 7-11, 47166 Duisburg, Germany. gia@krebs-duisburg.de
- Journal
- Ann Hematol. 2008 May;87(5):345-52. Epub 2008 Feb 12.
- Abstract URL
- Click here to view abstract
